Quantcast

Latest Cougar Biotechnology Inc. Stories

2011-06-03 06:30:00

CHICAGO, June 3, 2011 /PRNewswire/ -- Data related to ZYTIGA(TM) (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The studies were sponsored by Ortho Biotech Oncology Research & Development, unit of Cougar Biotechnology, Inc. "We are pleased that these data have been selected for presentation at the 2011 ASCO Annual Meeting," said William N. Hait, M.D., Ph.D., Global Therapeutic Area Head, Ortho Biotech...

2011-05-25 16:26:00

HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(TM) (abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo. The COU-AA-301...

2010-12-20 17:15:00

HORSHAM, Pa., Dec. 20, 2010 /PRNewswire/ -- Centocor Ortho Biotech Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Janssen-Cilag International NV also filed a marketing authorization application (MAA) with the European Medicines Agency (EMA)...

2010-09-09 17:05:00

LOS ANGELES, Sept. 9 /PRNewswire/ -- Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. Study...

2009-07-10 08:00:00

NEW BRUNSWICK, N.J., July 10 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Cougar Biotechnology, Inc., a development stage biopharmaceutical company with a specific focus on oncology. Johnson & Johnson's tender offer for shares of Cougar Biotechnology common stock expired at 5 p.m. Eastern Daylight Time (EDT) yesterday with approximately 20,148,930,000 shares tendered, representing approximately 95.9% of...

2009-07-03 07:53:00

NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that the initial offering period of its tender offer for all outstanding shares of common stock of Cougar Biotechnology, Inc. (Nasdaq: CGRB) expired at midnight (Eastern time) on July 2, 2009. The offer was conducted through a wholly owned subsidiary of Johnson & Johnson named Kite Merger Sub, Inc. The depositary for the tender offer has advised Johnson & Johnson that, as of...

2009-06-05 08:00:00

NEW BRUNSWICK, N.J., June 5 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ), through a new wholly-owned subsidiary, Kite Merger Sub, Inc., today will commence a cash tender offer to purchase all outstanding shares of common stock of Cougar Biotechnology, Inc. (Nasdaq: CGRB). Johnson & Johnson reported on May 21, 2009, its intent to acquire Cougar Biotechnology. Upon the successful closing of the tender offer, shareholders of Cougar Biotechnology will receive $43.00 in cash...

2009-05-22 11:33:00

CHICAGO, May 22 /PRNewswire/ -- Friday's "Sidewinder: Movers" video, hosted by www.ONN.tv contributor Kevin Cook, covers notable price action in the following securities: Cougar Biotechnology Inc. (CGRB) Salesforce.com (CRM) Archer-Daniels-Midland Co. (ADM) (Logo: http://www.newscom.com/cgi-bin/prnh/20090323/AQM046LOGO) Recorded live from downtown Chicago, the Sidewinder Report is a daily look at notable options activity and unusual price action. This video can be found on...

2009-05-21 18:06:00

Access to Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology NEW BRUNSWICK, N.J., and LOS ANGELES, May 21 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Cougar Biotechnology, Inc. (Nasdaq: CGRB), a development stage biopharmaceutical company with a specific focus on oncology, today announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer. Cougar Biotechnology,...

2008-10-23 09:00:38

Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." The Symposium is currently taking place in Geneva, Switzerland. The Phase II clinical trial of CB7630 (COU-AA-002) is being conducted at the University of California, San Francisco Comprehensive Cancer Center with...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related